Current Trends in the Treatment of Hepatocellular Carcinoma: Clinical Applications and Advancement

Hepatocellular carcinoma (HCC), sometimes termed liver cancer, is the most lethal form of the disease and the fifth most common form of cancer in humans. A major international health worry is the rising incidence of liver cancer. Forecasts indicate that by 2025, more than a million people each year will be diagnosed with liver cancer. Hepatocellular carcinoma is responsible for 90% of all cases of liver cancer. Of all cancers, HCC has the sixth highest incidence and third highest fatality rate worldwide. Cirrhosis risk is increased by both hepatitis B and c. Consumption of alcoholic beverages is a significant extra risk factor in the five times higher than hepatitis C. Nonalcoholic steatohepatitis (NASH), hepatitis D infection, and advanced age/male gender are additional risk factors. The multi-stage process that makes up HCC pathophysiology is complex. The first stages of hepatocyte malignant transformation and HCC development result from the interplay of different variables. No pathological evidence is necessary to confirm the diagnosis. Ultrasound, CT scans, and MRIs are just some of the radiologic exams that can be performed as part of a screening. Orthotopic liver transplantation (OLT) or surgical excision are the only treatments that guarantee a full recovery. Radiotherapy, systemic chemotherapy, molecularly targeted therapies, and cryoablation are other treatments. Tumor size, location, extrahepatic spread, and baseline liver function determine treatment. HCC commonly progresses in cirrhosis. Hepatitis B vaccination, universal blood product screening, safe injection practices, treatment and education of alcoholics and intravenous drug users, and early antiviral therapy can prevent HCC.